As both NfL and GFAP can be elevated in various neurological diseases [9, 10] without directly indicating inflammation, integrating inflammatory proteins such as cytokines into a biomarker panel could provide a more comprehensive assessment of the biology underlying MS. Here, GFAP is linked to myeloid sarcoma.